Tesamorelin: the clinical literature on this stabilized GHRH analog
Protected against DPP-IV degradation, this GHRH analog has been the subject of published clinical trials on visceral adipose tissue: a review of the literature.
Tesamorelin stands out among other GHRH analogs studied in research for a particularly high level of published clinical documentation, including controlled trials in peer-reviewed journals.
A specific chemical stabilization
Native human GHRH (1-44) is rapidly degraded by the enzyme DPP-IV (dipeptidyl peptidase-4). Tesamorelin addresses this issue by adding a trans-3-hexenoyl group at the N-terminal position, which protects the molecule from this enzymatic degradation and prolongs its availability to bind to the GHRH-R receptor.
Mechanism: the Gαs / cAMP / PKA pathway
Once bound to the GHRH-R receptor of pituitary somatotropic cells, Tesamorelin activates the Gαs → cAMP → PKA signaling pathway, stimulating the physiological pulsatile release of endogenous GH. Downstream, this stimulation results in an elevation of hepatic IGF-1 — the peripheral mediator of many effects attributed to the somatotropic axis in the literature.
Published clinical trials on lipodystrophy
A significant portion of the Tesamorelin literature comes from clinical trials conducted in an HIV patient population presenting with lipodystrophy (abnormal redistribution of adipose tissue). These trials, published notably in JAMA, documented a selective and significant reduction in visceral adipose tissue (on the order of −18% over 26 weeks), with no loss of subcutaneous tissue.
Reported metabolic effects
Beyond body composition, the clinical literature describes a favorable modulation of lipid markers (decreased triglycerides), with no major effect reported on blood glucose or insulin sensitivity in the studied cohorts — a point that distinguishes Tesamorelin from certain other modulators of the GH/IGF-1 axis.
Comparison with the CJC-1295 / Ipamorelin combination
Tesamorelin targets the same GHRH-R receptor as CJC-1295, but via a different chemical stabilization and without combination with a GHS-R1a secretagogue. Both approaches are frequently cited side by side in the comparative literature on strategies for stimulating the somatotropic axis.